Group 1 - The stock of MicroPort Scientific Corporation-B (02160.HK) has decreased by 7% [1] - As of the time of reporting, the stock price is at 0.93 HKD [1] - The trading volume reached 3.3167 million HKD [1]

【九安医疗】2025业绩预告：主业稳健，利润大幅增长主要系资产管理贡献 业绩概况： 2025全年：归母净利润20.2–23.5亿元（同比+21.05%~+40.83%）；扣非净利润20.7–24亿元（同比 +23.18%~+42.81%）。 2025Q4：归母净利润4.31–7.61亿元（同比+43.60%~+153.57%）；扣非净利润4.92–8.22亿元（同比+62.07%~+ 业绩概况： 2025全年：归母净利润20.2–23.5亿元（同比+21.05%~+40.83%）；扣非净利润20.7–24亿元（同比 +23.18%~+42.81%）。 2025Q4：归母净利润4.31–7.61亿元（同比+43.60%~+153.57%）；扣非净利润4.92–8.22亿元（同比 +62.07%~+170.77%）。 简评： 1）净利润同比增长主要系资管业务大类资产配置表现良好。 2）试剂盒类产品作为常规家用上呼吸道病毒筛查工具，以及家用医疗健康电子产品市场需求持续稳定。 【九安医疗】2025业绩预告：主业稳健，利润大幅增长主要系资产管理贡献 ...

消息面上，1月26日晚，微创心通发布公告称，董事会建议将公司股本按每5股每股面值0.000005美元的 已发行及未发行现有股份合并为1股每股面值0.000025美元的合并股份的基准实施股份合并。于公告日 期，现有股份以每手买卖单位1000股现有股份于联交所买卖。于股份合并生效后，于联交所买卖的每手 买卖单位将维持不变为1000股合并股份。 智通财经APP获悉，微创心通-B(02160)跌7%，截至发稿，跌7%，报0.93港元，成交额331.67万港元。 ...

Group 1 - In the stock market, Yingke Medical experienced a decline of 5.78%, with a current share price of 42.20 yuan, a trading volume of 1.28 billion yuan, a turnover rate of 0.63%, and a total market capitalization of 27.648 billion yuan [1] - Yingke Medical Technology Co., Ltd. is located in Zibo City, Shandong Province, and was established on July 20, 2009, with its listing date on July 21, 2017. The company's main business includes three segments: personal protection (91.47% of revenue), rehabilitation care (4.75%), and other products (3.77%) [1] Group 2 - From the perspective of major fund holdings, Chunhou Fund has one fund heavily invested in Yingke Medical. The Chunhou Times Preferred Mixed A Fund (014235) held 12,000 shares in the fourth quarter, unchanged from the previous period, accounting for 2.84% of the fund's net value, making it the fourth-largest holding. The estimated floating loss today is approximately 31,100 yuan [2] - The Chunhou Times Preferred Mixed A Fund (014235) was established on January 27, 2022, with a latest scale of 14.6472 million yuan. Year-to-date returns are 6.65%, ranking 3,570 out of 8,861 in its category; the one-year return is 39.41%, ranking 3,052 out of 8,126; and since inception, the return is 2.31% [2]

报告发布方：中金企信国际咨询 （4）运动医学类医疗器械：运动医学类医疗器械主要包括运动医学类植入物和有源设备及耗材，主要通过手术干预的方式在全关节镜或者关节镜辅助下对 韧带、关节囊、肌腱等软组织的形态修复以及功能重建时完全植入到人体内或者代替人体的某一组织的材料，用于运动医学手术中骨、肌腱、软组织之间的 固定或补偿自然韧带，包括带线锚钉、界面螺钉、带袢钛板、射频消融系统、刨削动力系统等。 我国运动医学领域的发展起步较晚，但增长速度位列细分领域前列。近年国来，运动医学的临床治疗逐步渗透至各大医院的骨科科室。根据中金企信数据， 2022年中国开展的运动医学关节镜手术数量约117.7万台，未来预计该增长趋势将继续保持，预测于2030年，中国开展的运动医学关节镜手术数量将达到约 350.6万台。2016年至2023年，我国运动医学类医疗器械市场规模由14亿元增长至50亿元，复合年增长率为19.94%，高于骨科植入耗材市场的整体增速。 2024年受运动医学国采执行影响，运动医学类医疗器械市场规模下降至46亿元。 中金企信自建数据库并搭建全路径数据矩阵，具备全球范围线上、线下数据资源约80亿条不同数据处理及背书能力。涉及 ...

Group 1 - On January 26, Dongxing Medical experienced a decline of 0.42% with a transaction volume of 43.62 million yuan [1] - The financing data on January 26 shows that Dongxing Medical had a financing purchase amount of 2.91 million yuan and a financing repayment of 10.15 million yuan, resulting in a net financing buy of -7.24 million yuan [1] - As of January 26, the total balance of margin trading for Dongxing Medical was 98.52 million yuan, with the financing balance accounting for 4.99% of the circulating market value, indicating a high level compared to the past year [1] Group 2 - As of January 20, the number of shareholders for Dongxing Medical was 8,993, a decrease of 3.31% from the previous period, while the average circulating shares per person increased by 3.42% to 7,579 shares [2] - For the period from January to September 2025, Dongxing Medical reported an operating income of 284 million yuan, a year-on-year decrease of 10.21%, and a net profit attributable to the parent company of -53.20 million yuan, a year-on-year decrease of 181.13% [2] Group 3 - Since its A-share listing, Dongxing Medical has distributed a total of 169 million yuan in dividends [3]

1月26日，美好医疗跌5.46%，成交额5.96亿元。两融数据显示，当日美好医疗获融资买入额4868.64万 元，融资偿还5884.57万元，融资净买入-1015.93万元。截至1月26日，美好医疗融资融券余额合计3.21 亿元。 融资方面，美好医疗当日融资买入4868.64万元。当前融资余额3.19亿元，占流通市值的1.74%，融资余 额超过近一年90%分位水平，处于高位。 分红方面，美好医疗A股上市后累计派现2.93亿元。 机构持仓方面，截止2025年9月30日，美好医疗十大流通股东中，国泰聚信价值优势灵活配置混合A （000362）位居第二大流通股东，持股591.79万股，为新进股东。华宝中证医疗ETF（512170）位居第 三大流通股东，持股481.27万股，相比上期减少88.13万股。香港中央结算有限公司位居第五大流通股 东，持股371.34万股，相比上期增加71.48万股。国泰金牛创新成长混合（020010）位居第六大流通股 东，持股361.79万股，为新进股东。鹏华新兴产业混合A（206009）位居第七大流通股东，持股357.58 万股，相比上期增加6.30万股。博时医疗保健混合A（050026 ...

1月26日，联影医疗涨0.32%，成交额12.85亿元。两融数据显示，当日联影医疗获融资买入额1.49亿 元，融资偿还1.62亿元，融资净买入-1319.08万元。截至1月26日，联影医疗融资融券余额合计14.70亿 元。 融资方面，联影医疗当日融资买入1.49亿元。当前融资余额14.68亿元，占流通市值的1.33%，融资余额 超过近一年90%分位水平，处于高位。 融券方面，联影医疗1月26日融券偿还3200.00股，融券卖出987.00股，按当日收盘价计算，卖出金额 13.22万元；融券余量1.04万股，融券余额139.46万元，低于近一年10%分位水平，处于低位。 资料显示，上海联影医疗科技股份有限公司位于上海市嘉定区城北路2258号，成立日期2011年3月21 日，上市日期2022年8月22日，公司主营业务涉及提供高性能医学影像设备、放射治疗产品、生命科学 仪器及医疗数字化、智能化解决方案。主营业务收入构成为：销售医学影像诊断设备及放射治疗设备 81.29%，提供维修收入13.56%，其他(补充)4.68%，软件收入0.47%。 截至9月30日，联影医疗股东户数3.24万，较上期增加96.28%；人均流 ...

1月26日，微电生理跌5.10%，成交额2.43亿元。两融数据显示，当日微电生理获融资买入额4009.15万 元，融资偿还2481.21万元，融资净买入1527.95万元。截至1月26日，微电生理融资融券余额合计3.66亿 元。 资料显示，上海微创电生理医疗科技股份有限公司位于上海市浦东新区周浦镇天雄路588弄1-28号第28 幢，成立日期2010年8月31日，上市日期2022年8月31日，公司主营业务涉及电生理介入诊疗与消融治疗 领域创新医疗器械研发、生产和销售。主营业务收入构成为：导管类产品71.77%，其他产品20.22%， 设备类产品7.24%，租赁服务0.77%。 截至9月30日，微电生理股东户数9580.00，较上期增加9.00%；人均流通股13033股，较上期减少 8.26%。2025年1月-9月，微电生理实现营业收入3.36亿元，同比增长15.65%；归母净利润4192.06万元， 同比增长0.46%。 机构持仓方面，截止2025年9月30日，微电生理十大流通股东中，汇添富创新医药混合A（006113）位 居第一大流通股东，持股472.84万股，相比上期增加30.86万股。汇添富医疗服务灵活配 ...

Group 1 - The core viewpoint of the news is that 麦澜德 experienced a decline in stock price and has significant financing activities, indicating a high level of market interest and potential volatility [1] - As of January 26, 麦澜德's stock price fell by 3.09%, with a trading volume of 95.12 million yuan, and a net financing purchase of 1.08 million yuan [1] - The total financing and securities balance for 麦澜德 reached 125 million yuan, with a financing balance of 124 million yuan, accounting for 7.41% of the circulating market value, indicating a high level compared to the past year [1] Group 2 - As of September 30, 麦澜德 had 6,402 shareholders, an increase of 17.23%, while the average circulating shares per person decreased by 14.70% [2] - For the period from January to September 2025, 麦澜德 reported a revenue of 344 million yuan, a year-on-year increase of 4.01%, while the net profit attributable to shareholders was approximately 96 million yuan, a slight decrease of 0.07% [2] - 麦澜德 has distributed a total of 297 million yuan in dividends since its A-share listing, with 247 million yuan distributed over the past three years [3] Group 3 - As of September 30, 2025, among the top ten circulating shareholders of 麦澜德, 华夏稳增混合 (519029) ranked fourth with 701,500 shares, a decrease of 550,500 shares from the previous period [3] - Notably, 中信建投轮换混合A (003822), 中信建投甄选混合A (008347), and 汇添富成长焦点混合 (519068) have exited the list of top ten circulating shareholders [3]